A61P 5/22
For decreasing, blocking or antagonising the activity of calcitonin
Official title: for decreasing, blocking or antagonising the activity of calcitonin
A61P5/22 (For decreasing, blocking or antagonising the activity of calcitonin) appears on 51 US grants and 78 published applications in this corpus.
Search patents in A61P- Granted patents
- 51
- Published applications
- 78
- Assignees
- 54
- Inventors
- 146
- Latest grant
- 27 Aug 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 2 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 1 |
| 2002 | 0 | 4 |
| 2003 | 2 | 4 |
| 2004 | 2 | 6 |
| 2005 | 2 | 6 |
| 2006 | 1 | 4 |
| 2007 | 4 | 2 |
| 2008 | 1 | 4 |
| 2009 | 4 | 1 |
| 2010 | 0 | 7 |
| 2011 | 2 | 3 |
| 2012 | 5 | 8 |
| 2013 | 1 | 1 |
| 2014 | 4 | 5 |
| 2015 | 3 | 2 |
| 2016 | 3 | 5 |
| 2017 | 2 | 2 |
| 2018 | 2 | 3 |
| 2019 | 4 | 2 |
| 2020 | 0 | 3 |
| 2021 | 2 | 2 |
| 2022 | 0 | 0 |
| 2023 | 2 | 0 |
| 2024 | 1 | 1 |
| 2025 | 0 | 1 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Extended recombinant polypeptides and compositions comprising same27 Aug 2024US 12,071,456 B2Amunix Pharmaceuticals, Inc.
- Adjunctive therapy with 25-hydroxyvitamin D and articles therefor29 Aug 2023US 11,738,033 B2Eirgen Pharma Ltd.
- Treating headache comprising administering an antibody to calcitonin gene-related peptide17 Jan 2023US 11,555,064 B2Teva Pharmaceuticals International GmbH
- Adjunctive therapy with 25-hydroxyvitamin D and articles therefor18 May 2021US 11,007,205 B2Eirgen Pharma Ltd.
- Extended recombinant polypeptides and compositions comprising same30 Mar 2021US 10,961,287 B2Amunix Pharmaceuticals, Inc.
- Pharmaceutical compositions of polymeric micellar cinacalcet, and methods of preparation and use thereof16 Jul 2026US 2026/0199234 A1Hangzhou Shixi Pharmaceutical Technology Co., Ltd.
- Extended recombinant polypeptides and compositions comprising same13 Feb 2025US 2025/0051405 A1Amunix Pharmaceuticals, Inc.
- Treatment material11 Jul 2024US 2024/0226403 A1Broad Bean Science Co., Ltd.
- Extended recombinant polypeptides and compositions comprising same9 Sep 2021US 2021/0277074 A1Amunix Pharmaceuticals, Inc.
- Adjunctive Therapy With 25-Hydroxyvitamin D And Articles Therefor26 Aug 2021US 2021/0260079 A1Eirgen Pharma Ltd.
Most cited
By later US patents
- Oral peptide pharmaceutical products108US 6,086,918 AUnigene Laboratories Inc. · 2000
- Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein92US 6,756,480 B2Amgen Inc. · 2004
- 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition79US 7,550,455 B2Boehringer Ingelheim International GmbH · 2009
- Extended recombinant polypeptides and compositions comprising same70US 8,673,860 B2Amunix Operating Inc. · 2014
- 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals67US 8,106,060 B2Boehringer Ingelheim International GmbH · 2012